Beranda532523 • BOM
add
Biocon Ltd
Tutup sebelumnya
₹390,35
Rentang hari
₹390,30 - ₹396,85
Rentang tahun
₹290,80 - ₹424,95
Kapitalisasi pasar
474,09 M INR
Volume Rata-Rata
121,51 rb
Rasio P/E
81,58
Hasil dividen
0,13%
Bursa utama
NSE
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (INR) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 41,73 M | 9,20% |
Biaya operasional | 25,16 M | 17,78% |
Penghasilan bersih | 1,44 M | 472,91% |
Margin laba bersih | 3,45 | 422,73% |
Penghasilan per saham | 2,74 | 1.986,89% |
EBITDA | 7,13 M | 0,91% |
Tarif pajak efektif | 23,60% | — |
Neraca
Total aset
Total liabilitas
| (INR) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 61,04 M | 130,29% |
Total aset | — | — |
Total liabilitas | — | — |
Total ekuitas | 330,55 M | — |
Saham yang beredar | 1,33 M | — |
Harga terhadap nilai buku | 1,88 | — |
Tingkat pengembalian aset | — | — |
Tingkat pengembalian modal | 1,60% | — |
Arus Kas
Perubahan kas bersih
| (INR) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | 1,44 M | 472,91% |
Kas dari operasi | — | — |
Kas dari investasi | — | — |
Kas dari pembiayaan | — | — |
Perubahan kas bersih | — | — |
Arus kas bebas | — | — |
Tentang
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. The company was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Didirikan
29 Nov 1978
Kantor pusat
Situs
Karyawan
16.420